Bal Pharma Limited — Board Meeting, 29-05-2025: Outcome of Board Meeting

Bal Pharma has announced a board meeting outcome approving the financial results for the quarter and half-year. Consolidated revenue hit ₹303 Cr, with a PAT of ₹72.4 Cr for FY25, slightly down from ₹74.5 Cr last year. A dividend of Re 1.20 per share (12%) was declared. The merger of Golden Drugs Pvt Ltd is complete. New internal, cost, and secretarial auditors were appointed. Despite losses in some subsidiaries, the company is optimistic about turnaround supported by fresh funds and new brand launches, maintaining focus on pharma operations with stable margins and restructuring progress.